MUSCLE SPASM IMPACTS ~84% OF U.S. ADULTS

Awaken to the possibility of relief

 

First Patient Enrolled in Phase 3, RESUME-1

Neurana Pharmaceuticals is developing a novel, non-opioid, non-drowsy,

non-cognitive impairing treatment for acute and painful muscle spasms

 

 

NEURANA - 

Bringing new treatment options for muscle spasms

Neurana’s lead product, tolperisone, has a pharmacological profile that may offer unique benefits to patients suffering from muscle spasms

TODAY
TOLPERISONE

The only non-sedating, non-drowsy, non-opioid muscle relaxant in clinical development

1990s
Tizanidine
(Zanaflex®)
Orphenadrine/
Aspirin/Caffeine 
(Orphenadrine Compound®) 
2000s
Cyclobenzaprine
(Flexeril® ER) 
1980s
Baclofen
(Lioresal®)
Carisprodol/Aspirin 
(Soma Compound®) 
Carisprodol/Aspirin/
Codeine 
(Soma Compound with Codeine®) 
1970s
Dantroline
(Dantrium®)
Cyclobenzaprine 
(Flexeril®) 
1960s
Metaxalone
(Skelaxin®)
Methocarbamol
(Robaxin®)
1950s
Chlorzoxazone
(Parafon Forte®, Lorzone®)
Carisoprodol
(Soma®)
Orphenadrine
(Norflex®)
TimelineMarker_2000s.png
Today.png
1950s.png
1970s.png
1900s.png

Put your cursor over years in the timeline to see the history of muscle spasm treatment options

 
 

TEAM

Visionary management and investors committed to reducing the pain and disability that can accompany acute muscle spasms

Sinnova.jpg
HIG_BioHealthPartners_Web.jpg
Longitude-Logo.png
NLVP_logo_header.png
161_MagnaSci_Ventures.jpg
Hale-BioPharma-Ventures-Logo.jpg